Bastian Dehmel

Corporate Officer/Principal presso OCULIS HOLDING AG

54 anni

Health Technology

Consumer Services

Posizioni attive di Bastian Dehmel

Società	Posizione	Inizio	Fine
OCULIS HOLDING AG	Corporate Officer/Principal	01/01/2022	-

Società	Posizione	Inizio	Fine
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Direttore Tecnico/Scientifico/R&S	01/10/2017	01/12/2021
Amgen (Europe) GmbH	Corporate Officer/Principal	01/12/2013	01/07/2017

Freie Universität Berlin

Doctorate Degree

Distribuzione geografica

Posizioni

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Doctorate Degree	1

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
OCULIS HOLDING AG	Health Technology

Aziende private	2
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology
Amgen (Europe) GmbH

Aziende private

Health Technology

Amgen (Europe) GmbH